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B cells are involved in immune thrombocytopenia (ITP) pathophysiology by producing antiplatelet auto-
antibodies. However more than a half of ITP patients do not respond to B cell depletion induced by
rituximab (RTX). The persistence of splenic T follicular helper cells (TFH) that we demonstrated to be
expanded during ITP and to support B cell differentiation and antiplatelet antibody-production may
participate to RTX inefﬁciency. Whereas it is well established that the survival of TFH depends on B cells
in animal models, nothing is known in humans yet. To determine the effect of B cell depletion on human
TFH, we quantiﬁed B cells and TFH in the spleen and in the blood from ITP patients treated or not with
RTX. We showed that B cell depletion led to a dramatic decrease in splenic TFH and in CXCL13 and IL-21,
two cytokines predominantly produced by TFH. The absolute count of circulating TFH and serum CXCL13
also decreased after RTX treatment, whatever the therapeutic response. Therefore, we showed that the
maintenance of TFH required B cells and that TFH are not involved in the inefﬁciency of RTX in ITP.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
B cells participate in immune thrombocytopenia (ITP) patho-
physiology by producing auto-antibodies against glycoproteins
expressed on platelets, thus leading to their phagocytosis by splenic
macrophages [1]. T Follicular Helper cells (TFH) represent a major T
cell subset involved in B cell differentiation and proliferationwithinmediated cytotoxicity; AID,
center; ITP, immune throm-
cells; PBL, peripheral blood
cells.
iment B3, 2 rue Angelique
udia).lymphoid organs [2]. Their role in autoimmunity has been
demonstrated in the sanroque mouse model [3]. These mice do not
express Roquin, a negative regulator of ICOS which results in the
expansion of TFH that stimulate germinal center (GC) formation
and the production of autoantibodies leading to a lupus-like
phenotype. Interestingly, the adoptive transfer of TFH from sanro-
que mice into naïve mice triggers similar autoimmune manifesta-
tions. On the contrary, the disruption of TFH and B cell interaction
abrogates autoimmune manifestations and leads to a decrease in
TFH frequency, thus underlining the bidirectional crosstalk be-
tween TFH and B cells, and the requirement of B cells for TFH sur-
vival. Indeed, it has been shown that GC B cell are particularly
involved in the maintenance of TFH within secondary lymphoid
organs in mice [4,5]. These cognate B-T cell interactions sustain TFH
response by presenting antigen and via the ICOS-L/ICOS and CD40/
CD154 signaling pathways [4].
S. Audia et al. / Journal of Autoimmunity 77 (2017) 89e9590We recently showed that splenic TFH are expanded during ITP
and support B cell differentiation and antiplatelet antibody-
production [6]. We speculated that rituximab (RTX), a B cell
depleting therapy that is increasingly used to treat autoimmune
diseases (AID) could regulate TFH numbers, in the blood and in
lymphoid organs. Recent reports showed that the expansion of
circulating TFH is reversed after RTX treatment in type 1 diabetes
[7] and granulomatosis with polyangeitis [8]. Similarly, the level of
a key chemokine produced by TFH, CXCL13, that binds to CXCR5
and participates to the recruitment of CXCR5þ B cells within GC,
decreases after RTX treatment [9,10]. Surprisingly, a combination of
low dose RTX associated with mycophenolate mofetil and tacroli-
mus used to prevent kidney rejection, was reported to induce GC B
cell (CD19þCD38þBcl6þ) depletion without affecting TFH [11], thus
contradicting what is observed in mice [4,5]. As both RTX and
splenectomy are used to treat ITP [12,13], we aimed to clarify
whether the survival of TFH depends on B cells in humans by
investigating the effect of B cell depletion on circulating and splenic
TFH in ITP patients treated with RTX.2. Material and methods
2.1. Patients
Forty-three primary persistent/chronic ITP patients were
included in the study for either blood or spleen analyses (blood and
spleen samples were both available for only two patients). Blood
samples, obtained from a cohort of 23 patients, were used to
investigate the effect of RTX on circulating B cells and TFH, and to
attempt to determine predictive factors of response by comparing
responders to non-responders to RTX (Table 1). Peripheral blood
mononuclear cells (PBMC) were isolated by gradient centrifugation
and stored in liquid nitrogen at the Biological Resource Center
Ferdinand Cabanne (BB-0033-00044) until needed.
Splenocytes were obtained from a second cohort of 22 patients
(Table 2) as previously described [14] and stored in liquid nitrogen
until needed. Splenocytes were used to determine the effect of RTX
on the immune response in vivo by comparing RTX-untreated pa-
tients (n ¼ 13) to patients treated with RTX prior to splenectomy
(n ¼ 9). Of note, all RTX-treated patients underwent splenectomy
because a response was not achieved. Splenocytes from RTX-
untreated patients were also used for certain experiments to
determine the effect of RTX on splenocytes in vitro.Table 1
Characteristics of primary chronic ITP patients (blood analyses).
Responders to ritu
Age (years), median [IQ range] 55.8 [37.4e71.5]
Gender ratio (female/male) 6/6
Disease duration (months), median [IQ range] 7.4 [2.6e30]
Nadir of platelet count within the 2 months prior to RTX
(109/L), median [IQ range]
11 [7e19]
Previous treatments, n (%)
Steroids 12 (100)
IVIg 6 (50)
Dapsone 5 (42)
TPO-RA 1(8)
Hydroxychloroquine 1 (8)
Splenectomy 1 (8)
Treatment within the 2 weeks prior to rituximab, n (%)
Steroids 6 (50)
IVIg 1 (8)
Dapsone 1 (8)
TPO-RA 1 (8)
None 2 (16)
ITP: immune thrombocytopenia; IVIg: intravenous immunoglobulins; TPO-RA: thromboAll patients gave an informed consent in accordance with the
declaration of Helsinki. The study was approved by the institutional
review board and the ethics committee of our University Hospital.
Response to RTX was deﬁned as an increase in platelet count above
30 G/L with at least a doubling of the baseline level 8 weeks after
RTXwas started. Patients not achieving a platelet count above 30 G/
L with at least a doubling of the pretreatment baseline level or who
needed rescue therapy after the 8 weeks following the ﬁrst RTX
infusion were considered as non-responders, as recommended
[15].
2.2. Flow cytometry
The following antibodies were used for ﬂow cytometry (FCM):
anti-CD19 Allophycocyanin (APC), anti-CD38 PhycoErythrin (PE),
anti-IgD Fluorescein isothiocyanate (FITC), anti-CD3 Brillant Violet
510, anti-CD4 PE-Cyanin7, anti-CXCR5 PerCP-Cy5.5, anti-ICOS APC,
anti-PD-1 FITC. Data were acquired on a BD Biosciences LSRII cy-
tometer (Flow cytometry department, IFR 100, Burgundy Univer-
sity) and analyzed with FlowJo® software.
2.3. In vitro B cell depletion
To assess the effect of RTX on TFH in vitro, splenocytes (1.106/mL)
from RTX-untreated ITP patients were cultured in RPMI supple-
mented with 5% heat inactivated fetal bovine serum and 1%
glutamine and incubated with RTX (rituximab, Roche). RTX was
used at 10 mg/ml, a concentration that allows the saturation of CD20
on cell surface [16] and corresponds to residual concentration of
RTX during its therapeutic use [17]. To test the role of complement
in B cell depletion, 5% of rabbit serum was added to culture. Cells
were harvested after 1, 3 and 6 days for ﬂow cytometry staining. B
cells were identiﬁed by CD19 expression. The efﬁcient binding of
RTX to B cells was checked by using an anti-CD20 antibody binding
the same epitope of RTX: in this condition, B cells exposed to
RTX were CD19þCD20. TFH were deﬁned as
CD3þCD4þCXCR5þICOSþPD-1hi.
2.4. Cytokine measurement
For cytokine measurement, serum was isolated within four
hours following blood collection and was stored in liquid nitrogen
at the Biological Resource Center Ferdinand Cabanne (BB-0033-ximab n ¼ 12 Non-responders to rituximab n ¼ 11 p-value
63.1 [47.2e79.3] 0.25
2/9 0.2
52.5 [3.5e166] 0.09
10 [4e19] 0.08
11 (100) e
7 (64) 0.7
4 (36) 1
1 (9) 1
1 (9) 1
0 1
7 (64) 0.7
3 (27) 0.3
0 1
1 (9) 1
0 0.5
poietin receptor agonists.
Table 2
Characteristics of splenectomized primary ITP patients.
RTX-untreated ITP n ¼ 13 RTX-treated ITP n ¼ 9 p-value
Age (years), median [IQ range] 27.5 [22e52] 71 [47e79] 0.002
Gender ratio (female/male) 11/2 6/3 0.6
Disease duration (months), median [IQ range] 20 [12e42] 16 [10e30] 0.5
Platelet count within the 2 months prior to splenectomy
(109/L), median [IQ range]
22.5 [17e27] 15 [10e22] 0.2
Previous treatments, n (%)
Steroids 13 (100) 8 (89) 0.4
IVIg 9 (69) 9 (100) 0.1
Dapsone 8 (62) 5 (56) 1
Rituximab 0 9 (100) <0.0001
TPO-RA 0 2 (22) 0.2
Vincristine 0 1 (11) 0.4
Treatment within the 2 weeks prior to splenectomy, n (%)
IVIg 8 (61) 7 (78) 0.6
Steroids 3 (23) 1 (11) 0.6
Dapsone 1 (8) 0 1
TPO-RA 0 1 (11) 0.4
None 1 (8) 0 1
Responder to splenectomy, n (%) 12 (92) 6 (67) 0.3
Duration between rituximab and splenectomy (months), median [IQ range] e 7.2 [5.6e9.3] e
ITP: immune thrombocytopenia; IVIg: intravenous immunoglobulins; TPO-RA: thrombopoietin receptor agonists.
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16,000 rpm for 5 min to remove clots or precipitates prior to
cytokine measurement. A multiplex bead immunoassay (eBio-
science) was used to simultaneously measure CXCL13 and IL-21,
following manufacturer's instructions. Data were acquired and
analyzed on a Bio-Plex® 200 system for multiplex analysis (Bio-
Rad; Flow cytometry department, IFR 100, Burgundy University).
2.5. CD4þ T cell separation
Splenocytes or PBMCwere incubated with anti-CD4 microbeads
(Miltenyi), following fabricant's instructions. Separations were
performed with an AutoMACS device (Miltenyi). Purity, assessed by
FCM, was >97%.
2.6. Gene expression quantiﬁcation
RNA extraction was performed by using the RNeasy RNA-DNA-
miRNA Universal kit (Qiagen) as recommended by the manufac-
turer. RNA was retrotranscribed by using the iScript (Qiagen) and
the expression of CXCR5, CXCL13, IL-21 and GAPDH mRNA was
quantiﬁed by quantitative PCR (qPCR) by using the following spe-
ciﬁc primer pairs: CXCR5: fw CTGGAGGACC-TGTTCTGGGA, rev
AGGAGGAAGATGAGGCTGTAG, IL-21: fw GCCACATGATTAG-
AATGCGTC, rev TTCAGGGACCAAGTCATTCAC, CXCL13: fw
GCTCAAGTCTGAACTCTACCTC, rev TCTCTTGGACACATCTACACCT,
GAPDH: fw ATGGGGAAGGTGAAGGTCG, rev GGGGTCATTGATGG-
CAACAATA. qPCR was performed on a Quantstudio 12K real-time
PCR system (Life technologies) using the following thermal cycle
conditions: 50 C for 2 min, 95 C for 10 min, 40 cycles at 95 C for
1 s and 60 C for 30 s in the presence of the Sybr Select mastermix
(Life technologies) and 500 nM forward and reverse primers. Gene
expression values were calculated according to the comparative
threshold cycle method [18] using the stable expressed GAPDH as
endogenous control. The value of the lowest expressed sample was
set as one and used to calculate fold change (FC) of target genes.
2.7. Immunohistochemistry
Anti-Bcl6 (Dako) and anti-PD-1 (Abcam) antibodies were used.
Staining was performed using a BenchMark Ultra instrument
(Ventana Medical Systems, Roche diagnostic). Visualization wasbased on enzymatic conversion of diaminobenzidine (DAB) into a
brown-colored precipitate by horseradish peroxidase at the site of
antigen localization. Ultra Red (Ventana Medical Systems) and DAB
were used successively to perform double staining.2.8. Statistical analysis
Data are given by median [interquartile range], excepted when
speciﬁed. Fisher's exact test was used to compare qualitative data.
Quantitative values from RTX-untreated and RTX-treated patients
are represented as scatter plots andwere compared by usingMann-
Whitney test. Sequential data from responders and non-responders
to RTX are represented by before/after plots and were compared by
using the Wilcoxon matched-pairs test. The paired t-test was used
to compare the average of cell depletion by RTX in vitro. P < 0.05
was considered signiﬁcant.3. Results
3.1. Rituximab induces a dramatic decrease in splenic TFH in vivo
As TFH are known to support B cell differentiation within
lymphoid organs, immunohistochemistry was used to localize
them within the spleen of ITP patients. In RTX-untreated patients,
follicles were clearly identiﬁed and displayed a prominent germinal
center (GC). TFH were localized within GC, as demonstrated by the
PD-1 and Bcl6 staining (Fig. 1A). On the contrary, nor follicles nor
TFH were observed in RTX-treated patients (data not shown).
The frequencies of CD19þ B cells and TFH, deﬁned as
CD3þCD4þCXCR5þICOSþPD-1hi, were determined among spleno-
cytes by FCM and compared between RTX-untreated and RTX-
treated patients (Fig. 1B). As expected, we observed a complete B
cell depletion in almost all RTX-treated patients as compared to
untreated ones (0.6% [0.3e4] vs. 58.2% [52e63] of total lympho-
cytes, P ¼ 0.0003; Fig. 1C). B cell depletion was associated with a
profound decrease in CXCR5þCD4þ T cells and most particularly in
TFH (0.1% [0.05e0.23] vs. 2% [1.4e3.2], P ¼ 0.001; Fig. 1D). Con-
ﬁrming these results, CXCR5 expression in splenic CD4þ T cells was
decreased (Fig. 1E). Furthermore, the expression of CXCL13 and IL-
21, two cytokines produced by TFH [2,6] were also diminished in
RTX-treated patients compared to untreated ones (Fig. 1E).
Fig. 1. Effect of rituximab on splenic cells in vivo. A) PD-1 (red) and Bcl6 (brown) staining was used to localized TFH within the spleens by immunohistochemistry. Representative
spleen of one RTX-untreated ITP patient showing a follicle with germinal center (magniﬁcation 10 and 35). B) Frequencies of splenic B cells and TFH were determined by ﬂow
cytometry. Representative dot plots of one rituximab-untreated and one rituximab-treated ITP patient. C) Splenocytes from RTX-untreated ITP patients (black circles) or treated
with rituximab prior to splenectomy (open circles) were compared for B cell frequency, D) CXCR5þ and TFH (CXCR5þICOSþPD-1hi) frequencies, measured by ﬂow cytometry, and for
E) the expression of CXCR5, CXCL13 or IL-21, measured by qPCR in CD4þ T cells. The horizontal bar represents the median with interquartile range, FC: fold changes. P-value derived
by Mann-Whitney test.
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To determine whether RTX could deplete TFH, splenocytes from
RTX-untreated patients were cultured in vitro with RTX and/or
complement. B cell and TFH frequencies were determined by FCM
as represented in Fig. 2A. It is established that the major mecha-
nism of B cell depletion by RTX is antibody-dependent cell-medi-
ated cytotoxicity (ADCC), but as a type 1 IgG monoclonal antibody,
RTX also strongly activates complement that increases effector cell
functions [19]. Consistent with these mechanisms of action, B cell
depletion was around 50% at day 1, reaching 80% (P ¼ 0.05) after 3
days and 90% (P ¼ 0.001) at day 6 in presence of complement,
whereas it represented only 35% (P ¼ 0.13) without complement at
day 6 (Fig. 2B). Contrary to the rapid B cell depletion induced by
RTX with complement, TFH frequency decreased slowly overtime,
representing 60% of baseline level at day 6 (P ¼ 0.007). Without
complement, only a partial B cell depletion was achieved and TFH
frequency was nearly not affected, representing an average of 93%
of baseline level at day 6 (P ¼ 0.2). To conﬁrm the absence of direct
interaction between RTX and TFH, we measured CD20 expression
on TFH by FCM. TFH did not express CD20, which was conﬁrmed byadding RTX just before the staining, as the mean ﬂuorescence in-
tensity (MFI) was not affected, whereas it was completely abolished
on B cells (Fig. 2C).
Altogether, these results rather argue for an indirect effect of
RTX on TFH due to B cell depletion than for a direct effect of RTX on
TFH.3.3. Rituximab induces a decrease in the absolute number of
circulating TFH
The effect of RTX on circulating cells was determined before and
3 months [range: 2.5e4.3] after RTX treatment. As observed in the
spleen, B cell depletionwas also evident in the blood of RTX-treated
patients (Fig. 3A), while the frequency of circulating CD4þCXCR5þ
was not affected (Fig. 3B). However, when TFH were speciﬁcally
studied, their number diminished after RTX treatment (687
[280e914] vs. 239 cells/mL [106e366]; P ¼ 0.001), whatever the
therapeutic response, further arguing for a role of B cells to their
maintenance (Fig. 3B). The pretreatment absolute counts of TFH
were not different between responders and non-responders
(P ¼ 0.9, data not shown).
Fig. 2. Effect of rituximab on splenic cells in vitro. A) Splenocytes from 3 rituximab-untreated ITP patients were cultured in presence or not of rituximab (RTX: 10 mg/mL) and
rabbit complement (cpt, 5%). The frequencies of B cells (CD19þ), CD4þCXCR5þ and TFH (ICOSþPD1þ in CD4þCXCR5þ) were determined by ﬂow cytometry. Representative dot plots of
one spleen after 6 days of culture. B) B cell (triangles, dashed line) and TFH frequencies (squares, full line) were determined by ﬂow cytometry at day 1 (d1), d3 and d6. Cell
frequency is expressed as a percentage of untreated cells. P-value derived by paired t-test. Only signiﬁcant differences with baseline level are represented: *: P < 0.05; **: P < 0.01 C)
CD20 expression reported as mean ﬂuorescence intensity (MFI) on TFH (left panel) and B cells (right panel) at baseline (grey shaded histogram) or after 30 min culture with
rituximab (blank histogram). A representative histogram of one ITP patient is shown.
Fig. 3. Effect of rituximab on circulating cells and serum cytokines. ITP patients were compared before (black circles) and 3 months after rituximab treatment (open circles) for
A) B cell frequency and B) CXCR5þ T cell and TFH (CXCR5þICOSþPD-1hi) frequencies in the peripheral blood as determined by ﬂow cytometry. C) The expression of CXCR5, CXCL13
and IL-21 was measured by quantitative PCR in circulating CD4þ T cells. P-value derived by Wilcoxon matched-pairs test, FC: fold changes. D) CXCL13 was measured by multiplex
immunoassay in the serum of ITP patients before (n ¼ 22) and after (n ¼ 16) RTX treatment (upper panel). The horizontal bar represents the median with interquartile range. P-
value derived by Mann-Whitney test. Paired-data are depicted in a before-after graph for 16 patients (lower panel). P-value derived by Wilcoxon matched-pairs test. PBL: peripheral
blood lymphocytes.
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S. Audia et al. / Journal of Autoimmunity 77 (2017) 89e9594CXCL13 and IL-21 are two cytokines predominantly produced by
TFH that are increased during several AID (ANCA-associated
vasculitis [9], rheumatoid arthritis [20], type 1 diabetes [7], sicca
syndrome [21]). As both CXCL13 [22] and IL-21 [23] serum con-
centrations have been reported to be increased in ITP, wemeasured
their expressions in circulating CD4þ T cells and in serum before
and after RTX treatment. Probably due to the low proportion of TFH
among circulating CD4þ T cells, CXCR5, CXCL13 and IL-21 expres-
sions were unchanged after RTX treatment (Fig. 3C). In our hands,
serum IL-21 was not detected (data not shown). Interestingly,
serum CXCL13 tended to be lower in patients treated with RTX than
in untreated ones (60.7 ng/mL [29.4e114] vs. 94 [71.7e234.7],
P ¼ 0.08, Fig. 3D). When paired samples were considered, a sig-
niﬁcant decrease in CXCL13 was observed after RTX (100
[68.6e298.5] to 54.9 ng/mL [28.2e100.7]; P ¼ 0.008), and most
particularly in patients who responded to RTX (data not shown).
Serum CXCL13 concentration was not correlated with circulating
TFH frequency or absolute number (data not shown). Altogether
these results show that B cell depletion is associated with a
decrease in circulating TFH and serum CXCL13 concentration,
whatever the therapeutic response to RTX.
The determination of predictive factors of response to RTX re-
mains a critical issue to manage ITP patients. Thus, we compared
age, sex, disease duration, serum CXCL13, absolute count of TFH and
B cell subsets before RTX treatment, between responders and non-
responders. Despite none of these parameters were signiﬁcantly
associated with therapeutic response to RTX (data not shown), it is
worth noticing that non-responders tended to have a longer dis-
ease duration than responders (7.4 [2.6e30] vs. 52.5 [3.5e166]
months, P ¼ 0.09, Table 1).
4. Discussion
We here show that B cell depletion obtained by RTX in vivo is
associated with a decrease in TFH both in the blood and in the
spleen of ITP patients, a phenomenon that we conﬁrmed in vitro,
thus demonstrating that B cells participate to the maintenance of
TFH in human secondary lymphoid organs, similarly to what is
observed in animals [4,5]. As a complete B cell depletion was ach-
ieved following RTX, we were not able to determine whether a
particular subset of B cells was speciﬁcally involved in TFH persis-
tence. In animals, GC B cells support TFH survival [4,5], whereas in
humans, their role seems less prominent, as showed byWallin et al.
[11]. In their study, they analyzed lymph nodes from patients
treated with RTX in association with mycophenolate mofetil and
tacrolimus before kidney engraftment, to avoid acute transplant
rejection. Although patients were treated with 500 mg RTX one
month before, only a partial B cell depletion within lymph nodes
was achieved and preferentially affected GC B cells. The frequency
of TFH that were deﬁned as CD4þCXCR5þCD57þ was not different
from patients not treated with RTX. Different factors could explain
the discrepancies between these results and our study. First, it has
been shown in monkeys that B cell depletion was not similar be-
tween lymphoid organs, especially, that B cell depletion is more
difﬁcult to be achieved in lymph nodes than in the spleen [24].
Secondly, different dosages of RTX were used: 2 g in our study vs.
500 mg in the aforementioned paper, a dosage that could be
insufﬁcient to induce a total B cell depletion within lymphoid
organs.
Interestingly, we observed a progressive decrease in TFH fre-
quency following B cell depletion in vitro. RTX mechanism of action
relies on ADCC that is even more efﬁcient with complement acti-
vation [25,26], a phenomenon we conﬁrmed by showing an in-
crease in B cell depletion in presence of complement. The direct
effect of RTX on TFH was ruled out as they do not express CD20,supporting the fact that their progressive decline was due to the
disruption of survival signal following B cell depletion, notably by
the loss of stimulation through ICOS, as previously described
[27,28]. However, as TFH were quantiﬁed by FCM, it cannot be
excluded that their decrease was due to changes in their pheno-
type. In mice, in the absence of cognate antigen stimulation, TFH
downregulate CXCR5, PD-1 and Bcl6 and survive in secondary
lymphoid organs as memory cells [4,29]. After subsequent antigen
stimulation, these quiescent memory TFH are activated, expressed
CXCR5 and PD-1 again and provide efﬁcient B cell costimulation
[29]. Thus, in patients who relapse after a ﬁrst response to RTX
treatment, one can hypothesize that the persistence of TFH in such
a memory state could support the differentiation of autoreactive B
cells during the reconstitution of the B cell compartment. Unfor-
tunately, such a hypothesis will be hardly demonstrated in humans,
as lymphoid organs from responder patients could not obviously be
assessed.
Whether the decrease in TFH following RTX therapy we
observed is speciﬁc of ITP or represents a general mechanism
cannot be fully answered. However, the literature reported a
decrease in circulating TFH following B cell depletion during type 1
diabetes [7] and granulomatosis with polyangeitis [8]. Moreover,
we also measured TFH within the spleen of a patient suffering from
autoimmune hemolytic anemia, who was previously treated with
RTX. No B cells were detected and splenic TFH frequency repre-
sented 0.06% of total CD4þ T cells, a percentage that is similar to the
onewemeasured in RTX-treated ITP patients. Thus, it argues for the
fact that B cell depletion induced by RTX is responsible for a
decrease in circulating and splenic TFH, whatever the disease and
the response to treatment.
In ITP, the mechanisms that lead to thrombocytopenia rely on
both an inappropriate bone marrow platelet production and a pe-
ripheral destruction of platelets due to autoantibodies produced by
B cells [1] or to a CD8þ Tcell-mediated cytotoxicity [30]. At a patient
level, one mechanism could be predominantly involved, thus
leading to variable response to treatment, as observed in murine
models [31]. To date, no predictive factors of response to RTX have
clearly been established, even if RTX appeared to be more efﬁcient
in patients with disease duration of less than one year and who
previously responded to steroids [32]. In line with this, we
observed that non-responders to RTX tended to have a longer
disease duration compared to responders. Biomarkers that will
help identifying patients with a preferential B cell-mediated dis-
ease are thus required. Here, we cannot identify a clear predictive
factor of response to RTX. As previously shown, in those non
responder patients, platelet destruction can be due to the persis-
tence of long-lived speciﬁc plasma cells in the spleen [33], or in the
bonemarrowwhere their survival do not rely on IL-21 produced by
TFH [34], or due to cytotoxic T cell mediated cytotoxicity [30,35].
Thus, even if B cells are depleted and TFH no more present in
secondary lymphoid organs, other mechanisms maintain the
disease.
5. Conclusions
In conclusion, our data support a role for B cells in TFH survival
as a signiﬁcant decrease in TFHwas observed both in the spleen and
in the blood, whatever the response to RTX.
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